REMEGEN：2025FIRSTQUARTERLYREPORT.pdf

1、Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relian

2、ce upon the whole or any part of the contents of this announcement.RemeGen Co.,Ltd.*榮 昌 生 物 製 藥(煙 台)股 份 有 限 公 司(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:9995)2025 FIRST QUARTERLY REPORTThis announcement is made pursuant to Rules 13.09(2)(

3、a)and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance(Chapter 571 of the Laws of Hong Kong).Reference is made to the“RemeGen Co.,Ltd.2025 First Quarterly R

4、eport”published by RemeGen Co.,Ltd.*(the“Company”)on the website of the Shanghai Stock Exchange,for reference purpose only.The following is a translation of the 2025 First Quarterly Report of the Company solely for the purpose of providing information.Should there be any discrepancies,the Chinese ve

5、rsion shall prevail.The board of directors of the Company(the“Board”)reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited,have been reviewed by the audit committee but have not been reviewed by the independent

6、auditors of the Company.The unaudited financial data in the 2025 First Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the Peoples Republic of China instead of the International Financial Reporting Standards,and is prepared pursuant to the re